Size: | Price | Quantity | |
---|---|---|---|
100 mg | $100.00 | ||
500 mg | $400.00 |
Nalmefene (58895-64-0) is an opioid antagonist. Very similar activity profile to naloxone (Cat.# 10-2442) however displays slower onset and longer duration of action.1 Antagonizes the effects of salvinorin2 (κ-agonist) as well as herkinorin3 (μ-agonist). Nalmefene as been used as a therapeutic for treatment of alcohol dependence.4
References/Citations:
1) Osborn et al. (2010), In vivo characterization of the opioid antagonist nalmefene in mice; Life Sci., 86 624
2) Butelman et al. (2009), Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in non-human primates: fast onset and entry in cerebrospinal fluid; J. Pharmacol. Exp. Ther., 328 588
3) Butelman et al. (2008), The effects of herkinorin, the first mu-selective ligand from salvinorin A-derived scaffold, in neuroendocrine biomarker assay in nonhuman primates; J. Pharmacol. Exp. Ther., 327 154
4) Soyka and Rosner (2008), Opioid antagonists for pharmacological treatment of alcohol dependence – a critical review; Curr. Drug Abuse Rev., 1 280
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Nalmefene (58895-64-0) is an opioid antagonist. Very similar activity profile to naloxone (Cat.# 10-2442) however displays slower onset and longer duration of action.1 Antagonizes the effects of salvinorin2 (κ-agonist) as well as herkinorin3 (μ-agonist). Nalmefene as been used as a therapeutic for treatment of alcohol dependence.4
References/Citations:
1) Osborn et al. (2010), In vivo characterization of the opioid antagonist nalmefene in mice; Life Sci., 86 624
2) Butelman et al. (2009), Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in non-human primates: fast onset and entry in cerebrospinal fluid; J. Pharmacol. Exp. Ther., 328 588
3) Butelman et al. (2008), The effects of herkinorin, the first mu-selective ligand from salvinorin A-derived scaffold, in neuroendocrine biomarker assay in nonhuman primates; J. Pharmacol. Exp. Ther., 327 154
4) Soyka and Rosner (2008), Opioid antagonists for pharmacological treatment of alcohol dependence – a critical review; Curr. Drug Abuse Rev., 1 280
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.